- About the Fund
- Our Work With States
- The Milbank Quarterly
- Newsletter & Updates
The Milbank Memorial Fund is an endowed operating foundation that works to improve the health of populations by connecting leaders and decision makers with the best available evidence and experience.
Learn about the MMF
June 24, 2016
As the end of the month approaches, so does the end of phase one of SMART-D, the State Medicaid Alternative Reimbursement and Purchasing Test for High-Cost Drugs. A project of the Center for Evidence-based Policy (CEbP) at Oregon Health and Science University, SMART-D is part of a series of grants from the Laura and John Arnold Foundation in Houston, Texas, that address the rising cost of pharmaceutical drugs. SMART-D is aimed at developing a better menu of options for states to consider in purchasing high-cost drugs in Medicaid.
June 8, 2016
It is projected that by 2050, 83.7 million Americans will be over the age of 65, almost double the number who were that age in 2012. During its fall 2015 meetings, the Milbank Memorial Fund’s Reforming States Group turned its attention to the topic, partnering with The New York Academy of Medicine to develop sessions focused on some of the major challenges and opportunities facing states as they look at ways to support an aging population.
The new report, “How Can States Support an Aging Population? Actions Policymakers Can Take,” by Lindsay Goldman and Robert Wolf of the New York Academy of Medicine, provides a review of the issues discussed at the meetings, as well as recommendations for state policy interventions.
May 20, 2016
More and more attention is being paid to the social determinants of health—the conditions in which people are born, grow, work, live, and age, including factors such as income support, education, transportation, and housing—and their contribution to health and well-being. Despite all the evidence about how the factors affecting our health dwarf the impact of the health care we receive, it remains a challenge for state leaders to act. Why don’t state budgets reflect what we know about improving the health of populations? What are examples where, in spite of the barriers, these challenges are being overcome?
This report, written by Elizabeth Bradley, faculty director of the Yale Global Health Leadership Institute, and Erika Rogan, attempts to answer these questions. Based on focused discussions with state and local public health sector leaders, the report identifies the root causes for states not making overall budget and policy decisions that optimize their population’s health.
||Read more news|
Christopher F. Koller
President of the
Milbank Memorial Fund
With threats of lawsuits and pressure from government officials, some payers appear to be relaxing their coverage guidelines for expensive direct-acting antiviral drugs (DAAs), including drugs for Hepatitis C. The benefits that increased access to these drugs provide to patients with Hepatitis C—and to the drugs’ manufacturers and investors—will come at the expense of state budgets and, more importantly, broader discussions about matching demand for health care services to limited resources.